Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 89.5 kDa.
APC
Excitation Wavelength: 640 nm
Emission Wavelength: 661 nm
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, 0.2% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
5e5 of anti-CD22 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human Siglec-2 Protein, His Tag (Cat. No. SI2-HA2H4) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). APC signal was used to evaluate the binding activity (QC tested).
5e5 of PBMCs were stained with APC-Labeled Human Siglec-2 Protein, His Tag (Cat. No. SI2-HA2H4) and anti-CD3 antibody, washed and then analyzed with FACS. FITC signal was used to evaluate the expression of CD3+ T cells in PBMCs, and APC signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Moxetumomab pasudotox | HA-22; GCR-8015; CAT-8015 | Approved | Astrazeneca Plc | Lumoxiti | United States | Leukemia, Hairy Cell | Innate Pharma | 2018-09-13 | Leukemia; Leukemia, Hairy Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Prolymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Inotuzumab Ozogamicin | WAY-207294; PF-5208773; CMC-544; PF-05208773 | Approved | Wyeth Pharmaceutical Co Ltd, Celltech Group plc | Besponsa | EU | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Pfizer Europe Ma Eeig | 2017-06-28 | Lymphoma, B-Cell; Leukemia, Myelogenous, Chronic; Hematologic Neoplasms; Leukemia; Neoplasm, Residual; Hematopoietic stem cell transplantation (HSCT); Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Leukemia, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Burkitt Lymphoma | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
AUTO-3 | AUTO-3 | Phase 2 Clinical | University College London | Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti CD22 CAR-T cell therapy (Shanghai Yake Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd, The First Affiliated Hospital Of Zhejiang University School Of Medicine, Beijing Gao Boren Hospital Co Ltd, Chengdu USino Technology Biology Co Ltd | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CART22-cells | CART22-cells; JJO686 | Phase 2 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
Anti-CD22-CAR T cell therapy (Kecellitics Biotech) | Phase 2 Clinical | Kecellitics Biotech Company Ltd | Lymphoma, B-Cell; Leukemia; Lymphoma | Details | |
Epratuzumab-cys-tesirine | ADCT-602 | Phase 2 Clinical | Adc Therapeutics Sa | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Leukemia; Lymphoma | Details | |
Anti-CD22 CAR-T cell therapy (No. 307 Hospital) | Phase 2 Clinical | The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital) | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
UCART-20x22 | UCART-20x22 | Phase 2 Clinical | Cellectis Sa | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
TAC-001 | TAAC-001 | Phase 2 Clinical | Tallac Therapeutics Inc | Solid tumours | Details |
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma | Details |
KQ-2002 | KQ-2002 | Phase 2 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Lymphoma, B-Cell; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
Fourth-gen CAR T Cells Targeting CD19/CD22 therapy(Essen Biotech) | Phase 2 Clinical | Essen Biotech | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma; Central Nervous System Lymphoma | Details | |
CD19/CD22 Bispecific CAR-T Cell Therapy(Beijing Tongren Hospital) | Phase 2 Clinical | Beijing Tongren Hospital, Cmu | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Firicabtagene autoleucel | CRG-022 | Phase 2 Clinical | Cargo Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19/CD22 CAR-T cell therapy (The First Affiliated Hospital Of Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) therapy (KK Women's and Children's Hospital) | Phase 2 Clinical | Kk Women'S And Children'S Hospital | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
anti-CD22-CAR-transduced T cells(Southwest Hospital) | Phase 2 Clinical | Southwest Hospital | Leukemia; Lymphoma | Details | |
CD19/22 Bi-specific CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) | 4SCAR19/22 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) | CT-120 | Phase 2 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
CD19/CD22 dual-target CAR-T (Yake biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
HY-004 (Juventas) | HY-004 (Juventas) | Phase 2 Clinical | Juventas Cell Therapy Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
SCRI-CAR22v2 | Phase 2 Clinical | Seattle Children'S Hospital | Leukemia; Lymphoma | Details | |
CD19/CD22 CAR-T cell therapy (Federal Research Institute of Pediatric Hematology, Oncology and Immunology) | Phase 2 Clinical | Federal Research Institute of Pediatric Hematology Oncology and Immunology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma | Details | |
UCART-22 | UCART-22 | Phase 2 Clinical | Cellectis Sa | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Lymphoma, B-Cell; Neoplasm, Residual; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
TRPH-222 | CD22-4AP; TRPH-222; CAT-02-106 | Phase 1 Clinical | Catalent Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin | Details |
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) | Phase 1 Clinical | Shanghai Jiaotong University, Shanghai General Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) | Phase 1 Clinical | Stanford University, Orca Biosystems Inc | Neoplasm, Residual; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19/CD22 CAR-T cell therapy (Shenzhen BinDeBio) | Phase 1 Clinical | Dehe Biotech Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD22 CAR T cell therapy (Shanghai GeneChem) | Phase 1 Clinical | Shanghai Genechem Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD19- and CD22 specific CAR (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Lymphoma | Details | |
RD-102 | RD-102 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse | Details |
YT-19/22 | Phase 1 Clinical | China Immunotech Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
TriCAR T-cells | Phase 1 Clinical | Children'S Hospital Los Angeles | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
anti-CD19/anti-CD22 CAR T-cell therapy (MD Anderson Cancer Center/National Cancer Institute) | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Dual Anti-CD19/Anti-CD22 CAR-T Cell Therapy (Stanford University) | Phase 1 Clinical | Stanford University | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD10 CAR T-cell therapy (Zhujiang Hospital/Nanfang Hospital) | Phase 1 Clinical | Southern Medical University Zhujing Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD22/CD19 monoclonal antibody-toxin conjugate | Phase 1 Clinical | The University Of Texas Southwestern Medical Center | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
B-019 | B-019 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Leukemia, Lymphoid; Central Nervous System Lymphoma | Details | |
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy(St. Jude Children'S Research Hospital) | Phase 1 Clinical | St. Jude Children'S Research Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Autologous CD19/CD22 CAR T cells therapy(Instituto De Investigación Hospital Universitario La Paz) | Phase 1 Clinical | Instituto De Investigación Hospital Universitario La Paz | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
UB-VV400 | UB-VV400 | Phase 1 Clinical | Umoja BioPharma Inc, Iaso Biotherapeutics Ltd | Lymphoma, B-Cell; Autoimmune Diseases; Lymphoma, Non-Hodgkin | Details |
BZE-2204 | BZE2204; BZE-2204 | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Lymphoma, B-Cell; Multiple Myeloma | Details |
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells therapy(Stanford University) | Phase 1 Clinical | Stanford University, The Leukemia And Lymphoma Society | Leukemia; Lymphoma, B-Cell, Marginal Zone; Leukemia, Hairy Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Waldenstrom Macroglobulinemia; Burkitt Lymphoma | Details | |
Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy(Beijing GoBroad Hospital) | Phase 1 Clinical | Beijing GoBroad Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Allogeneic CD22-directed CAR T Cell Therapy(Sana Biotechnology) | SC262; SC-262 | Phase 1 Clinical | Sana Biotechnology Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
AUTO-1-NG | AUTO-1-NG; AUTO1/22 | Phase 1 Clinical | Autolus Therapeutics Plc, University College London | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma | Details |
Autologous CD22 targeting CAR-T cells therapy(British Columbia Cancer Agency) | CLIC-2201 | Phase 1 Clinical | British Columbia Cancer Agency | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
CD22 CAR-T Cell Therapy (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Solid tumours; Sarcoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
REGN5837 | REGN5837; REGN-5837 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
bispecific CD19/CD22 CAR T-cell therapy (University of Colorado) | Phase 1 Clinical | University Of Colorado | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
LCAR-AIO | LCAR-AIO; VHH CAR-T | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
ThisCAR-T-22(Fundamenta Therapeutics) | ThisCAR-T-22 | Phase 1 Clinical | Fundamenta Therapeutics Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
CD19x22 CAR T Cell Therapy (University Of Colorado Denver) | Phase 1 Clinical | University Of Colorado, Denver, Usa | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) | HX-s001; YTS101; HX-s001/YTS101; HXYT-001 | Phase 1 Clinical | Beijing Qingyi Taike Pharmaceutical Technology Co Ltd, China Immunotech Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
Anti-human CD19-CD22 T cell therapy | HR004 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Central Nervous System Lymphoma | Details |
Rezetamig | JNJ-8780; JNJ75348780; JNJ-75348780 | Phase 1 Clinical | Teneobio Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid) | Phase 1 Clinical | Wuhan BioRaid Biotechnology Co Ltd | Lymphoma, B-Cell; Multiple Myeloma | Details | |
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University, Shanghai YaKe Biotechnology Co Ltd | Hematologic Neoplasms | Details | |
JCAR-018 | JCAR-018 | Phase 1 Clinical | National Cancer Institute, Opus Bio | Lymphoma, B-Cell; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic | Details |
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
CTA-101 | CTA-101 | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
Anti-CD22 chimeric antigen receptor T cell therapy (Yake Biotechnology) | Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti CD19/CD22 chimeric antigen receptor T cell therapy (Yake Biotechnology) | Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
This web search service is supported by Google Inc.